Loading…
SpyGlass Pharma, Inc. is projected to rise to $23.25 by 2027, a +3% move from its current price of $22.53. SGP is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $21.73 | $22.52 | $23.33 | -0.06% |
| Aug 3 | $21.40 | $22.50 | $23.66 | -0.12% |
| Aug 4 | $21.15 | $22.49 | $23.92 | -0.18% |
| Aug 5 | $20.93 | $22.48 | $24.13 | -0.24% |
| Aug 6 | $20.75 | $22.46 | $24.32 | -0.30% |
| Aug 7 | $20.58 | $22.45 | $24.49 | -0.36% |
| Aug 8 | $20.42 | $22.44 | $24.65 | -0.42% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $20.42 | $22.44 | $24.65 | -0.42% |
| Week 2 | $19.56 | $22.34 | $25.52 | -0.83% |
| Week 3 | $18.91 | $22.25 | $26.19 | -1.24% |
| Week 4 | $18.36 | $22.16 | $26.74 | -1.65% |
| Week 5 | $17.88 | $22.07 | $27.23 | -2.06% |
| Week 6 | $17.45 | $21.97 | $27.67 | -2.47% |
| Week 7 | $17.06 | $21.88 | $28.07 | -2.87% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), including novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients.
It also develops a non-IOL-based, ring-shaped, sustained-release implant with bimatoprost. SpyGlass Pharma, Inc. was formerly known as SpyGlass Ophthalmics, Inc. and changed its name to SpyGlass Pharma, Inc.
in April 2021. The company was incorporated in 2019 and is based in Aliso Viejo, California.
The stock trades in the healthcare sector with a current price of $22.72 and a market capitalization of $759.61M. It holds a market rank of 2555. The shares are characterized by a 30-day trading range between $17.84 and $28.93, with an annualized volatility of 70%.
The short-term technical picture shows bullish sentiment, with a support level at $18.20 and a resistance at $22.72.
A major floor 23.2% below — a decisive break under it would weaken the trend.
The nearest floor, 17.0% below — buyers have tended to step in here.
Price is pressing into resistance (0.8% away) — a breakout level to watch.
A major ceiling 15.0% above — clearing it would confirm fresh momentum.
Key SGP support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SGP market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $21.92 | Buy | $22.01 | Buy |
| MA 10 | $21.18 | Buy | $21.48 | Buy |
| MA 20 | $20.72 | Buy | $20.95 | Buy |
| MA 50 | $19.97 | Buy | $20.90 | Buy |
| MA 100 | $22.10 | Buy | $21.96 | Buy |
| MA 200 | — | Neutral | — | Neutral |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 61.01 | Neutral |
| Stoch RSI (14) | 90.20 | Sell |
| CCI (20) | 151.10 | Buy |
| Williams %R (14) | -6.44 | Info |
| MACD (12,26,9) | 0.25 | Buy |
| ROC (12) | 9.37 | Buy |
| Bollinger %B (20,2) | 0.95 | Neutral |
| Stochastic %K (14) | 93.56 | Sell |
| TRIX (15) | 0.22 | Buy |
| Awesome (5,34) | 1.70 | Buy |
| Ultimate (7,14,28) | 75.68 | Sell |
| Momentum (10) | 2.76 | Buy |
| Aroon Osc (25) | 96.00 | Buy |
| Hull MA (9) | 22.73 | Sell |
| ADX (14) | 11.85 | Neutral |
| ATR (14) | 0.61 | Info |
The market sentiment is BULLISH with RSI(14) at 60, and the 50-day simple moving average is $19.94. The 200-day moving average is not provided in the data. The stock shows a defined near-term range, with support at $18.20 and resistance at $22.72. Over the last 30 days, price action has oscillated between $17.84 and $28.93, reflecting notable volatility.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $17.56 | $22.53 | $28.00 | 0% | Neutral | |
| $16.94 | $23.25 | $34.49 | +3% | Neutral | |
| $16.04 | $23.42 | $37.07 | +4% | Neutral | |
| $14.30 | $21.99 | $36.56 | -2% | Neutral | |
| $17.96 | $28.96 | $50.14 | +29% | Bullish | |
| $20.40 | $34.39 | $61.66 | +53% | Bullish | |
| $19.92 | $35.03 | $64.76 | +55% | Bullish | |
| $19.84 | $36.33 | $69.04 | +61% | Bullish | |
| $18.55 | $35.33 | $68.85 | +57% | Bullish | |
| $18.69 | $37.00 | $73.78 | +64% | Bullish | |
| $25.26 | $56.14 | $123.07 | +149% | Bullish | |
| $45.80 | $101.79 | $234.11 | +352% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $17.56 | $22.53 | $26.64 | +0.00% |
| September 2026 | $17.11 | $20.82 | $26.46 | -7.58% |
| October 2026 | $17.30 | $21.34 | $27.66 | +2.49% |
| November 2026 | $17.19 | $21.45 | $28.25 | +0.51% |
| December 2026 | $16.62 | $20.96 | $28.00 | -2.28% |
Click any year to see its month-by-month SGP forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The SGP price prediction for 2026 points to an average of $22.53 (low $17.56, high $28.00) — a potential gain of 0% on today's $22.53. A consolidation phase looks the most probable path here.
In 2027, SGP is projected to trade between $16.94 and $34.49, averaging $23.25 — a potential gain of +3% from today's $22.53. That is up +3% on the projected 2026 average. Price action looks broadly range-bound.
SpyGlass Pharma, Inc.'s 2028 outlook centres on $23.42, within a $16.04 to $37.07 range. That is up +1% on the projected 2027 average. That marks a +4% change versus current levels. A consolidation phase looks the most probable path here.
By 2029, SGP could reach as high as $36.56, with a base case around $21.99 and support toward $14.30 — roughly -2% from $22.53. Price action looks broadly range-bound.
Expect SGP to range from $17.96 to $50.14 through 2030. The $28.96 average target implies a +29% move from current prices. That is up +32% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The SGP price prediction for 2031 points to an average of $34.39 (low $20.40, high $61.66) — a potential gain of +53% on today's $22.53. Momentum favours further upside here.
In 2032, SGP is projected to trade between $19.92 and $64.76, averaging $35.03 — a potential gain of +55% from today's $22.53. That is up +2% on the projected 2031 average. Buyers look set to stay in control over this stretch.
SpyGlass Pharma, Inc.'s 2033 outlook centres on $36.33, within a $19.84 to $69.04 range. That is up +4% on the projected 2032 average. That marks a +61% change versus current levels. Momentum favours further upside here.
By 2034, SGP could reach as high as $68.85, with a base case around $35.33 and support toward $18.55 — roughly +57% from $22.53. Buyers look set to stay in control over this stretch.
Expect SGP to range from $18.69 to $73.78 through 2035. The $37.00 average target implies a +64% move from current prices. That is up +5% on the projected 2034 average. Momentum favours further upside here.
The SGP price prediction for 2040 points to an average of $56.14 (low $25.26, high $123.07) — a potential gain of +149% on today's $22.53. Buyers look set to stay in control over this stretch.
In 2050, SGP is projected to trade between $45.80 and $234.11, averaging $101.79 — a potential gain of +352% from today's $22.53. That is up +81% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in SGP today (≈ 44.385264 SGP) could be worth
$4,517.89
+$3,517.89 (+352%) by 2050 · US Dollar
Based on the average projected SGP price of $101.79 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SGPwould be worth at today's price.
$1,000 invested in SGP on Feb 6, 2026 (≈ 37.878788 SGP) would be worth
$853.41
-$146.59 (-14.7%) today · 0.85× · US Dollar
Based on a SGP entry price of $26.4 vs. today's $22.53.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $20.49 | $1,099.56 | +10.0% |
| 1 month ago | $19.47 | $1,157.16 | +15.7% |
| 3 months ago | $23.98 | $939.53 | -6.0% |
| All time ago | $26.4 | $853.41 | -14.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SGP forecast.
Our base-case forecast reaches $45.00 around 2040.
Implied market cap at $45.00: $1.5B
The multi-year forecast lays out a trajectory from a neutral near term to a bullish longer-term path. The 2026 forecast shows an avg of $22.72 with a min of $17.56 and a max of $28.32 (ROI 0, sentiment NEUTRAL). The years 2027 and 2028 project avg prices of $23.60 and $23.81 with ROI values of 3.9 and 4.8, respectively, both still NEUTRAL.
In 2029 the avg is $22.43 with a negative ROI of -1.3 and NEUTRAL sentiment. By 2030 the avg rises to $30.09 with a 32.5 ROI and a BULLISH sentiment, continuing higher through 2031 ($35.74, 57.3), 2032 ($36.30, 59.8), 2033 ($37.80, 66.4), 2034 ($36.68, 61.5), and 2035 ($38.52, 69.5), all BULLISH. The forecast then expands sharply, with 2040 avg $59.01 and ROI 159.7, and 2050 avg $108.90 with ROI 379.3, both labeled BULLISH.
These figures illustrate a rising long-term trajectory with substantial upside potential, alongside the acknowledgement that forecasts are estimates and carry inherent uncertainty.
Tap a question to reveal the answer.
The 2030 forecast shows an avg of $30.09 with a min of $18.42 and a max of $52.64 and a ROI of 32.5, with sentiment BULLISH.
Near-term forecasts (2026–2029) are NEUTRAL, with 2026 avg $22.72 (ROI 0) and 2027–2028 modest gains (ROI 3.9 and 4.8). From 2030 onward, the outlook turns BULLISH with higher avg prices (e.g., 2030 avg $30.09) and positive ROIs (e.g., 32.5 in 2030, up to 379.3 by 2050). These are estimates and not guarantees.
Yes—the 2050 forecast lists a max of $250.48, with an avg of $108.90 and a bullish sentiment, indicating potential to reach higher price levels within the projection horizon.
The current price is $22.72 and the market cap is $759.61M.
The sentiment is BULLISH, RSI(14) is 60, the 50-day SMA is $19.94, the stock’s 30-day range is $17.84 to $28.93, with a support at $18.20 and a resistance at $22.72.
SpyGlass Pharma, Inc. Community Discussion
0Share your SpyGlass Pharma, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.